Oncologists who are treating patients with relapsed/refractory multiple myeloma should tailor therapeutical courses of action to the biology of the disease, frailty of the patient, and comorbidities, explains Natalie Callander, MD, professor (CHS), Hematology, Medical Oncology and Palliative Care.

In a video for oncology professionals, Dr. Callander discussed three principles for the treatment of patients with relapsed or refractory multiple myeloma. 

The principles include assessing where the patient is in their relapse, evaluating the type of myeloma that the patient is experiencing, and considering whether they meet the medical definition of frailty. 

An accompanying article summarized Dr. Callander's recent presentation on this topic at the National Comprehensive Cancer Network 12th Annual Congress in San Francisco, California. 

Resources:

• "Dr. Callander on Treatment Considerations in Multiple Myeloma," OncLive, October 9, 2017
• "Treatment for Relapsed/Refractory Multiple Myeloma Based on Biology, Time to Relapse," OncLive, October 8, 2017